AXNX Axonics
- 67.430
- +0.030+0.04%
- 67.000
- -0.430-0.64%
Axonics News
Needham Reiterates Hold on Axonics
Needham analyst Mike Matson reiterates Axonics with a Hold.
Needham: Reiterates that Axonics (AXNX.US) holds the rating.
Needham: Reiterates that Axonics (AXNX.US) holds the rating.
Axonics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 — Needham Reiterates → Hold 02/29/2024 5.61% RBC Capital → $71 Reiterates Sector Perform → Sec
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)
Axonics Q1 EPS $(0.38) Misses $(0.08) Estimate, Sales $91.41M Beat $89.59M Estimate
Axonics (NASDAQ:AXNX) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.08) by 375 percent. This is a 100 percent decrease over losses of $(0.19) per sh
Earnings Flash (AXNX) AXONICS Reports Q1 Revenue $91.4M
04:03 PM EDT, 04/30/2024 (MT Newswires) -- Earnings Flash (AXNX) AXONICS Reports Q1 Revenue $91.4M
Axonics 1Q Loss/Shr 38c >AXNX
Axonics 1Q Loss/Shr 38c >AXNX
Press Release: Axonics Reports First Quarter 2024 Financial Results
Axonics Reports First Quarter 2024 Financial Results IRVINE, Calif.--(BUSINESS WIRE)--April 30, 2024-- Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes inn
Press Release: Boston Scientific Announces Results for First Quarter 2024
Boston Scientific Announces Results for First Quarter 2024 PR Newswire MARLBOROUGH, Mass., April 24, 2024 MARLBOROUGH, Mass., April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX
Wells Fargo Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)
RBC Capital Remains a Hold on Axonics Modulation Technologies (AXNX)
UPDATE 1-FTC Seeks More Information on Boston Scientific's $3.7 Bln Axonics Deal
Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information
By Denny Jacob Boston Scientific and Axonics each received a request for additional information from the Federal Trade Commission regarding a previously agreed upon merger. The medical device manufa
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Axonics Stockholders Approve Boston Scientific Acquisition
Axonics Stockholders Approve Merger Agreement With Boston Scientific; Expected To Occur In The First Half Of 2024 And Remains Subject To Certain Conditions
Axonics, Inc. (NASDAQ:AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE:BSX). According to preliminary voting results f
Press Release: Axonics Stockholders Approve Merger Agreement With Boston Scientific
Axonics Stockholders Approve Merger Agreement with Boston Scientific IRVINE, Calif.--(BUSINESS WIRE)--March 22, 2024-- Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today t
Axonics Updates On Inter Partes Review Proceedings; Plans To Seek Review Of The PTAB's Finding That Remaining Claims Were Not Unpatentable
Today, the PTAB invalidated 10 of the 15 challenged claims in Medtronic's '314 patent and declined to invalidate the challenged claims in the '756 patent over one Administrative Patent Judge's dissent
Axonics Provides Update on Inter Partes Review Proceedings
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two
Gastroenterology Group of Naples Introduces Innovative Axonics Sacral Neuromodulation Therapy
New Treatment Option Offers Long-Term Relief for Those Suffering from Gastrointestinal Disorders NAPLES, Fla., March 19, 2024 /PRNewswire/ -- Gastroenterology Group of Naples, a partner practice of U
Analysis
Price Target
No Data
